Pharmaceuticals: Ubrolexin®
Active Ingredient
Cefalexin and Kanamycin.
Pharmaceutical form and application
Intramammary suspension.
Characteristics
Treatment of clinical mastitis in lactating dairy cows for bacteria susceptible to the combination of cefalexin and kanamycin such as Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis and Escherichia coli.
Application
For intramammary use.
Treat the infected quarter(s) twice, leaving an interval of 24 hours between treatments. Use the contents of one syringe (containing 200 mg cefalexin as monohydrate and 100,000 I.U. kanamycin as monosulphate) per quarter per treatment. Each syringe is for single use only.
Before infusion, the udder should be milked out completely, the teat should be thoroughly cleaned and disinfected and care should be taken to avoid contamination of the injector nozzle.
back to matrix